Detalhe da pesquisa
1.
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
Nature
; 551(7681): 517-520, 2017 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29132144
2.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30297397
3.
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 21(6): 786-795, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386568
4.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Lancet Oncol
; 19(4): 521-536, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545095
5.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
; 372(21): 2018-28, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891174
6.
Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
BMC Cancer
; 18(1): 413, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29649990
7.
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
BMC Cancer
; 18(1): 225, 2018 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29486723
8.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Lancet Oncol
; 18(1): 31-41, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932067
9.
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Lancet Oncol
; 17(3): 299-308, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26858122
10.
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med
; 369(2): 122-33, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724867
11.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
JAMA
; 315(15): 1600-9, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092830
12.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Lancet Oncol
; 16(3): 257-65, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25704439
13.
Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(20): 1986-1988, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29141165
14.
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development.
J Immunother Cancer
; 11(7)2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487665
15.
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
J Thorac Oncol
; 18(5): 587-598, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36646209
16.
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy.
Cancer Immunol Res
; 11(2): 164-170, 2023 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36512052
17.
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.
Cell Rep Med
; 4(1): 100868, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36513074
18.
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
J Thorac Oncol
; 18(1): 106-119, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36240972
19.
The use of immunotherapy in the first-line treatment of lung cancer.
Clin Adv Hematol Oncol
; 15(3): 190-192, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28398273
20.
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.
JTO Clin Res Rep
; 3(5): 100310, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35498382